To characterize clinical and pathological findings of rabbits evaluated at a veterinary teaching hospital because of dystocia.
Retrospective case series.
9 client-owned rabbits and 1 wild rabbit with signs of dystocia evaluated at a veterinary teaching hospital from 1996 through 2016.
Medical records of rabbits were reviewed to collect data on signalment; medical history; physical examination, laboratory, diagnostic imaging, and procedural findings; treatment; final diagnosis; and outcome. Data were summarized.
Dystocia in 7 rabbits was successfully managed through medical treatment, assisted vaginal delivery, or both (n = 6) or surgery alone (1); 3 rabbits were euthanized. Primiparous does, does ≤ 4 years old, and does of small breeds (< 2 kg [4.4 lb]) were most common. All client-owned rabbits had clinical signs of abnormal second-stage parturition, whereas the wild rabbit had only hemorrhagic vulvar discharge. Imaging was used to identify the number, size, and state of fetuses in most rabbits. Overall, 35 fetuses were accounted for, 25 of which were dead or later died. The cause of dystocia was determined for 8 rabbits and included fetal-maternal mismatch (n = 4), uterine inertia (2), fetal death or mummification (1), and stress-induced abortion (1).
CONCLUSIONS AND CLINICAL RELEVANCE
Obstructive dystocia from fetal macrosomia with or without secondary uterine inertia was the most common cause of dystocia in the evaluated rabbits. Although medical management was successful for many rabbits with dystocia in this study, surgery could still be required in other affected rabbits, particularly when fetal-maternal mismatch is involved.
Objective—To establish an objective method of determining proventricular diameter in psittacine birds by assessment of lateral whole-body radiographic views.
Design—Retrospective case-control study.
Animals—100 parrots with no signs of gastric disease and 19 parrots with signs of gastric disease.
Procedures—Measurements were obtained for the following variables: proventricular diameter at the level of the junction between the last thoracic vertebra and synsacrum, maximum distance between the dorsal serosa of the proximal aspect of the proventriculus and dorsal border of the sternum, maximum coelomic cavity height at the level of the proximal aspect of the proventriculus, and maximum dorsoventral height of the keel of the sternum. The ratio of proventricular diameter to each of those measurements was calculated and compared among species within the group without signs of gastric disease and between the gastric and nongastric disease groups.
Results—No significant differences were seen among species of parrots without signs of gastric disease for any ratio, but there were significant differences between parrots with gastric signs and those without gastric signs for all ratios. Only the proventricular diameterto-maximum dorsoventral height of the keel of the sternum ratio had no numeric overlap between groups. Sensitivity and specificity of the ratio for detection of proventricular enlargement were both 100%. Six causes associated with proventricular enlargement were identified.
Conclusions and Clinical Relevance—Evaluation of the proventricular diameter-to-keel height ratio is a new method for evaluating proventricular size in psittacines. Ratio values < 0.48 indicate normal proventricular diameter and the absence of proventricular disease.
OBJECTIVE To determine pharmacokinetics and sedative effects of buprenorphine after IV and oral transmucosal (OTM) administration in guinea pigs.
ANIMALS 14 male guinea pigs (6 adults for preliminary experiment; eight 8 to 11-week-old animals for primary study).
PROCEDURES A preliminary experiment was conducted to determine an appropriate buprenorphine dose. In the primary study, buprenorphine (0.2 mg/kg) was administered IV or OTM, and blood samples were obtained. The pH of the oral cavity was measured before OTM administration. Sedation was scored for 6 hours on a scale of 0 to 3 (0 = no sedation and 3 = heavy sedation). After a 7-day washout period, procedures were repeated in a crossover manner. Plasma buprenorphine concentration was quantified, and data were analyzed with a noncompartmental pharmacokinetic approach.
RESULTS Mean peak plasma buprenorphine concentrations were 46.7 and 2.4 ng/mL after IV and OTM administration, respectively. Mean time to maximum plasma buprenorphine concentration was 1.5 and 71.2 minutes, and mean terminal half-life was 184.9 and 173.0 minutes for IV and OTM administration, respectively. There was a range of sedation effects (0 to 2) for both routes of administration, which resolved within the 6-hour time frame.
CONCLUSIONS AND CLINICAL RELEVANCE On the basis of pharmacokinetic parameters for this study, buprenorphine at 0.2 mg/kg may be administered IV every 7 hours or OTM every 4 hours to maintain a target plasma concentration of 1 ng/mL. Further studies are needed to evaluate administration of multiple doses and sedative effects in guinea pigs with signs of pain.
To evaluate the pharmacokinetics of hydromorphone hydrochloride after IM and IV administration to orange-winged Amazon parrots (Amazona amazonica).
8 orange-winged Amazon parrots (4 males and 4 females).
Hydromorphone (1 mg/kg) was administered once IM. Blood samples were collected 5 minutes and 0.5, 1.5, 2, 3, 6, and 9 hours after drug administration. Plasma hydromorphone concentrations were determined with liquid chromatography-tandem mass spectrometry, and pharmacokinetic parameters were calculated with a compartmental model. The experiment was repeated 1 month later with the same dose of hydromorphone administered IV.
Plasma hydromorphone concentrations were > 1 ng/mL for 6 hours in 8 of 8 and 6 of 7 parrots after IM and IV injection, respectively. After IM administration, mean bioavailability was 97.6%, and mean maximum plasma concentration was 179.1 ng/mL 17 minutes after injection. Mean volume of distribution and plasma drug clearance were 4.24 L/kg and 64.2 mL/min/kg, respectively, after IV administration. Mean elimination half-lives were 1.74 and 1.45 hours after IM and IV administration, respectively.
CONCLUSIONS AND CLINICAL RELEVANCE
Hydromorphone hydrochloride had high bioavailability and rapid elimination after IM administration, with rapid plasma clearance and a large volume of distribution after IV administration in orange-winged Amazon parrots. Drug elimination half-lives were short. Further pharmacokinetic studies of hydromorphone and its metabolites, including investigation of multiple doses, different routes of administration, and sustained-release formulations, are recommended.
Objective—To determine pharmacokinetics after IV and oral administration of a single dose of tramadol hydrochloride to Hispaniolan Amazon parrots (Amazona ventralis).
Animals—9 healthy adult Hispaniolan Amazon parrots (3 males, 5 females, and 1 of unknown sex).
Procedures—Tramadol (5 mg/kg, IV) was administered to the parrots. Blood samples were collected from −5 to 720 minutes after administration. After a 3-week washout period, tramadol (10 and 30 mg/kg) was orally administered to parrots. Blood samples were collected from −5 to 1,440 minutes after administration. Three formulations of oral suspension (crushed tablets in a commercially available suspension agent, crushed tablets in sterile water, and chemical-grade powder in sterile water) were evaluated. Plasma concentrations of tramadol and its major metabolites were measured via high-performance liquid chromatography.
Results—Mean plasma tramadol concentrations were > 100 ng/mL for approximately 2 to 4 hours after IV administration of tramadol. Plasma concentrations after oral administration of tramadol at a dose of 10 mg/kg were < 40 ng/mL for the entire time period, but oral administration at a dose of 30 mg/kg resulted in mean plasma concentrations > 100 ng/mL for approximately 6 hours after administration. Oral administration of the suspension consisting of the chemical-grade powder resulted in higher plasma tramadol concentrations than concentrations obtained after oral administration of the other 2 formulations; however, concentrations differed significantly only at 120 and 240 minutes after administration.
Conclusions and Clinical Relevance—Oral administration of tramadol at a dose of 30 mg/kg resulted in plasma concentrations (> 100 ng/mL) that have been associated with analgesia in Hispaniolan Amazon parrots.
An 8-year-old sexually intact female eclectus parrot (Eclectus roratus) with a 4-day history of hyporexia and lethargy and a 1-day history of tenesmus was examined.
Severe leukocytosis characterized by severe heterophilia and moderate monocytosis was present. Marked dilation of the proventriculus and ventriculus and ascites were identified by means of radiography, coelomic ultrasonography, and contrast-enhanced CT, with no clinically relevant motility noted on ultrasonography. Results of coelomic fluid analysis were consistent with pyogranulomatous effusion. Endoscopy of the upper gastrointestinal tract following proventricular and ventricular lavage showed a thick caseous plaque occupying 30% of the caudal proventricular mucosa. Abundant yeast organisms were evident during cytologic examination of a proventricular and ventricular wash sample, and fecal culture yielded Candida glabrata.
TREATMENT AND OUTCOME
The bird was treated with SC fluids, assisted feedings, nystatin, fluconazole, amoxicillin–clavulanic acid, enrofloxacin, gastroprotectants, maropitant, and analgesics and slowly improved during hospitalization. A marked decrease in proventricular dilation was evident on serial radiographs obtained over a 12-month period. One year after diagnosis, the bird was presented with a 1-week history of hyporexia and lethargy, and fecal culture grew C glabrata. Antifungal treatment was resumed for 3 months. The bird had no clinical signs of infection 16 months after this recurrence, and subsequent fecal cultures were negative for fungal growth.
Findings illustrate the importance of upper gastrointestinal endoscopy in diagnosing proventricular and ventricular dilation in birds and emphasize the need for long-term antifungal treatment and monitoring in birds with fungal infections.
Objective—To evaluate agreement of 3 models of portable blood glucose meters (PBGMs; 2 designed for use with human samples and 1 designed for veterinary use) with a laboratory analyzer for measurement of blood glucose concentrations in ferrets (Mustela putorius furo).
Procedures—Samples were analyzed with 4 PBGMs (whole blood) and a laboratory analyzer (plasma). Two PBGMs of the model designed for veterinary use were tested; each was set to a code corresponding to canine or feline sample analysis throughout the study. Agreement and bias between measurements obtained with the PBGMs and the laboratory analyzer were assessed with Bland-Altman plots. Linear regression analysis was performed to evaluate associations with venipuncture site by comparison of central (jugular) and peripheral (lateral saphenous or cephalic) venous blood samples.
Results—Plasma glucose concentrations measured with the laboratory analyzer ranged from 41 to 160 mg/dL. Results from the PBGM for veterinary use coded to test a canine blood sample had the greatest agreement with the laboratory analyzer (mean bias, 1.9 mg/dL); all other PBGMs significantly underestimated blood glucose concentrations. A PBGM designed for use with human samples had the least agreement with the laboratory analyzer (mean bias, −34.0 mg/dL). Blood glucose concentration was not significantly different between central and peripheral venous blood samples for any analyzer used.
Conclusions and Clinical Relevance—Significant underestimation of blood glucose concentrations as detected for 3 of the 4 PBGMs used in the study could have a substantial impact on clinical decision making. Verification of blood glucose concentrations in ferrets with a laboratory analyzer is highly recommended.
Objective—To compare serum concentrations of liposome-encapsulated butorphanol tartrate (LEBT) and standard butorphanol tartrate (STDBT) following SC and IM administration, respectively, and to evaluate analgesic effects of LEBT and STDBT after parenteral administration to Hispaniolan parrots.
Animals—11 adult Hispaniolan parrots.
Procedure—The ability of LEBT to prolong the duration of analgesia in an avian species was tested. Blood samples were collected at serial time points after SC administration of LEBT (10 mg/kg or 15 mg/kg) or IM administration of STDBT (5 mg/kg). Serum concentrations of butorphanol tartrate were determined by use of a commercial immunoassay that measured parent drug and metabolites. Analgesic efficacy was evaluated in parrots exposed to electrical and thermal stimuli. Foot withdrawal thresholds were recorded at baseline and at serial time points after LEBT (15 mg/kg), liposome vehicle, STDBT (2 mg/kg), or physiologic saline (0.9% NaCl) solution administration.
Results—LEBT had a prolonged in vivo release for up to 5 days. Negligible serum butorphanol and butorphanol metabolite concentrations were obtained at 24 hours after IM administration of STDBT. Analgesic efficacy of LEBT as measured by foot withdrawal threshold to noxious thermal and electrical stimuli persisted for 3 to 5 days following SC administration of LEBT.
Conclusions and Clinical Relevance—SC administration of LEBT provided analgesia and detectable serum butorphanol concentrations in Hispaniolan parrots for up to 5 days. The use of LEBT may allow for substantial improvement in long-term pain relief without subjecting birds to the stress of handling and multiple daily injections.